International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 4 , Pages 1128-1133 , 15 July 2009

Dosimetric Impact and Theoretical Clinical Benefits of Fiducial Markers for Dose Escalated Prostate Cancer Radiation Treatment

Received 12 May 2008 ,Revised 1 September 2008 ,Accepted 6 September 2008.

References 

  1. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose–response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  2. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  3. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–988
  4. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  5. Balter JM, Lam KL, Sandler HM, et al. Automated localization of the prostate at the time of treatment using implanted radiopaque markers: Technical feasibility. Int J Radiat Oncol Biol Phys. 1995;33:1281–1286
  6. Langen KM, Pouliot J, Anezinos C, et al. Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:635–644
  7. Scarbrough TJ, Golden NM, Ting JY, et al. Comparison of ultrasound and implanted seed marker prostate localization methods: Implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:378–387
  8. Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1130–1137
  9. Greco C, Mazzetta C, Cattani F, et al. Finding dose–volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol. 2003;69:215–222
  10. Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: Dose–volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54:1314–1321
  11. Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000;46:391–402
  12. Peeters ST, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:1151–1161
  13. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose–volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:953–962
  14. Alber M, Belka C. A normal tissue dose response model of dynamic repair processes. Phys Med Biol. 2006;51:153–172
  15. Lyman JT. Complication probability as assessed from dose–volume histograms. Radiat Res Suppl. 1985;8:S13–S19
  16. Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135
  17. Niemierko A. Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Med Phys. 1997;24:103–110
  18. Alber M, Nusslin F. A representation of an NTCP function for local complication mechanisms. Phys Med Biol. 2001;46:439–447
  19. Zhang M, Moiseenko V, Liu M, et al. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: Result of organ motion simulations. Phys Med Biol. 2006;51:269–285
  20. Schaly B, Bauman GS, Song W, et al. Dosimetric impact of image-guided 3D conformal radiation therapy of prostate cancer. Phys Med Biol. 2005;50:3083–3101
  21. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002;54:1036–1046
  22. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  23. Tucker SL, Cheung R, Dong L, et al. Dose–volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:353–365
  24. Tucker SL, Dong L, Cheung R, et al. Comparison of rectal dose-wall histogram vs. dose–volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1589–1601
  25. Sohn M, Yan D, Liang J, et al. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose–volume–based normal tissue complication probability models. Int J Radiat Oncol Biol Phys. 2007;67:1066–1073
  26. Beltran C, Herman MG, Davis BJ. Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods. Int J Radiat Oncol Biol Phys. 2008;70:289–295
  27. Alonso-Arrizabalaga S, Brualla Gonzalez L, Rosello Ferrando JV, et al. Prostate planning treatment volume margin calculation based on the ExacTrac X-Ray 6D image-guided system: Margins for various clinical implementations. Int J Radiat Oncol Biol Phys. 2007;69:936–943
  28. van Herk M, Remeijer P, Rasch C, et al. The probability of correct target dosage: Dose–population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:1121–1135
  29. Cozzarini C, Fiorino C, Ceresoli GL, et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2 Gy). Int J Radiat Oncol Biol Phys. 2003;55:688–694
  30. Cassee J, Meijer G. The impact of an online gold markers protocol and IMRT on the rectal dose for prostate patients in a clinical settings. Radiother Oncol. 2007;84:S117
  31. Vargas C, Martinez A, Kestin LL, et al. Dose–volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:1297–1308
  32. Vargas C, Yan D, Kestin LL, et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose–volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys. 2005;63:141–149
  33. Fransson P, Bergstrom P, Lofroth PO, et al. Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique. Int J Radiat Oncol Biol Phys. 2006;66:430–438
  34. Nichol AM, Brock KK, Lockwood GA, et al. A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers. Int J Radiat Oncol Biol Phys. 2007;67:48–56
  35. Poggi MM, Gant DA, Sewchand W, et al. Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys. 2003;56:1248–1251
  36. Kupelian PA, Willoughby TR, Meeks SL, et al. Intraprostatic fiducials for localization of the prostate gland: Monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys. 2005;62:1291–1296
  37. Fiorino C, Reni M, Bolognesi A, et al. Intra- and inter-observer variability in contouring prostate and seminal vesicles: Implications for conformal treatment planning. Radiother Oncol. 1998;47:285–292
  38. Lee CT, Dong L, Ahamad AW, et al. Comparison of treatment volumes and techniques in prostate cancer radiation therapy. Am J Clin Oncol. 2005;28:618–625
  39. Balter JM, Cao Y. Advanced technologies in image-guided radiation therapy. Semin Radiat Oncol. 2007;17:293–297

 Conflict of interest: none.

PII: S0360-3016(08)03526-8

doi: 10.1016/j.ijrobp.2008.09.043

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 4 , Pages 1128-1133 , 15 July 2009